Thursday, June 5, 2014
Publication and contact
Adoptive cell therapy using
mutation-specific, CD4+ T cells in epithelial cancer
A single-patient study
suggests adoptive cell therapy using tumor mutation-specific, CD4+ T cells could help treat epithelial cancer. Ex
vivo, patient dendritic cells were transfected with RNAs representing 26
different patient-specific cancer mutations identified via whole-exome
sequencing and then cocultured with patient tumor-infiltrating lymphocytes
(TILs). Patient CD4+ T cells specifically recognized dendritic cells
presenting an ErbB2
interacting protein (ERBB2IP)
antigen with an E805G mutation. In the patient, adoptive transfer of about 10
billion ERBB2IPE805G mutation-specific, CD4+ T cells led to tumor regression that peaked at 7
months and disease stabilization for about 13 months. Next steps include
evaluating mutations in additional cancers that would be recognized by T
cells and amenable for use in mutation-specific, CD4+ T cell therapy.
Published online June 5, 2014
Patent application filed;
licensing status unavailable
Tran, E. et al. Science;
published online May 9, 2014;
Contact: Steven A. Rosenberg, National Cancer Institute,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]